EnteroBiotix has also appointed senior biotechnology executive Dr James Clark PhD as CEO, with founder Dr James McIIroy moving to the role of chief business officer in order to support the new CEO and accommodate NHS hospital requirements to complete his medical training as a clinician.
James Clark brings over 20 years of biotechnology and biopharmaceutical drug discovery, development and commercialisation experience to EnteroBiotix.
Previous roles have included chief technical officer at Enterome, one of Europe's leading microbiome companies, and most recently vice-president of clinical laboratory operations at Inivata, the global clinical cancer genomics group.
EnteroBiotix is developing novel medicinal products targeting the gut microbiome to serve patients with serious unmet clinical needs.
The company has established fully integrated ISO-accredited microbial collection and GMP-compliant processing capabilities under a 'specials' license from the MHRA.
Headquartered in Aberdeen, EnteroBiotix has to date raised over GBP 2m in equity investment and non-dilutive funding with a dedicated core team supported by an independent Scientific and Medical advisory board.
Bioforum, The Data Masters names new President
VolitionRx names new Chief Medical Officer
Quotient Sciences announces new appointments
Syndax Pharmaceuticals names new chief commercial officer
Everest Medicines names new chief medical officer and chief product officer
D3 Bio names new independent board member
Rigel Pharmaceuticals names new executive vice president and chief medical officer
Telix Pharmaceuticals names new group chief operating officer